30

Tianjin Chase Sun Pharmaceutical Co LtdSHE 300026 Stock Report

Last reporting period 30 Sep, 2023

Updated 01 Nov, 2024

Last price

Market cap $B

2.086

Small

Exchange

XSHE - Shenzhen Stock Exchange

300026.SZ Stock Analysis

30

Neutral

Based on Eyestock quantitative analysis, 300026.SZ`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

76/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

78.8 %

Greatly undervalued

Market cap $B

2.086

Dividend yield

0.81 %

Shares outstanding

3 309.56 B

Tianjin Chase Sun Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceutical products. The company is headquartered in Tianjin, Tianjin and currently employs 6,120 full-time employees. The company went IPO on 2009-10-30. The firm's main products include Chinese traditional formula granules, Xuebijing injection, fasudil hydrochloride injection, low molecular weight heparin calcium injection, bulk drugs and excipient, among others. The firm also provides medical apparatus and instrument. The firm distributes its products in domestic market and to overseas markets.

View Section: Eyestock Rating